Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).
Evan J. Lipson, MD, Johns Hopkins Medicine
Advertisement
Articles by Evan J. Lipson, MD, Johns Hopkins Medicine
Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.
Evan J. Lipson, MD, discusses the role of circulating tumor DNA testing in melanoma.
Advertisement
Latest Updated Articles
Dr. Lipson on the Current Treatment Landscape of Basal Cell CarcinomaPublished: June 30th 2022 | Updated:
Dr. Lipson on the Role of ctDNA Testing in MelanomaPublished: December 8th 2021 | Updated:
Balancing Safety and Efficacy in Adjuvant TherapyPublished: December 14th 2020 | Updated:
Adjuvant Clinical Trial Data Impact on Treatment SelectionPublished: December 14th 2020 | Updated:
Metastatic Melanoma Long-Term Survival DataPublished: December 14th 2020 | Updated:
Short-Term COVID-19 NCCN RecommendationsPublished: December 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5